Fevipiprant
Published , updated
Unassigned
New Medicines
Nasal polyposis with chronic rhinosinusitis (CRSwNP) and concomitant asthma
Information
New molecular entity
Novartis
Novartis
Development and Regulatory status
Discontinued
Discontinued
Discontinued
Feb 20
Development of fevipiprant discontinued as PIII LUSTER studies (in patients with asthma) failed to met primary outcome [3].
Category
A CRTh2 antagonist; also termed DP2 antagonist, targets prostaglandin D2 receptors
Nasal polyps are lesions arising from the nasal mucosa, occurring at any site in the nasal cavity or paranasal sinuses but most frequently seen in the clefts of the middle meatus. Nasal polyps can be considered as part of the spectrum of chronic rhinosinusitis. The population prevalence is reported as around 4%, with no racial predilection. The male-to-female ratio is approximately 2:1 [1].
Nasal polyposis with chronic rhinosinusitis (CRSwNP) and concomitant asthma
Oral